PAA
KRYS icon

Peregrine Asset Advisers’s Krystal Biotech KRYS Stock Holding History

Peregrine Asset Advisers’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$203K Buy
+547
New +$163K 0.04% 212

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Peregrine Asset Advisers's KRYS Position: Q2 2026 in Review

Peregrine Asset Advisers opened a new position in Krystal Biotech (KRYS) in Q2 2026: 547 shares worth $203K. The stake represents 0.04% of the portfolio and ranks #212 among its holdings.

422 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Peregrine Asset Advisers held 547 shares of Krystal Biotech worth $203K as of Q2 2026.
  • Krystal Biotech was a new Peregrine Asset Advisers position in Q2 2026.
  • Krystal Biotech made up 0.04% of Peregrine Asset Advisers's portfolio in Q2 2026, its #212 holding.
  • 422 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Peregrine Asset Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.